Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunitinib + prednisone
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**Sunitinib + prednisone** is an oral pharmaceutical combination used primarily in clinical investigation for metastatic castration-resistant prostate cancer (mCRPC), particularly in patients who have progressed after or during docetaxel-based chemotherapy. **Sunitinib** is a small molecule multi-targeted receptor tyrosine kinase inhibitor, blocking vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), KIT, RET, CSF-1R, and FLT3. **Prednisone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties, acting via the glucocorticoid receptor. The combination is studied both as second-line therapy (after docetaxel failure) and in combination with docetaxel for first-line treatment. In clinical trials, this combination improved progression-free survival (PFS) but not overall survival in mCRPC. Sunitinib is developed and manufactured by Pfizer[2][3][5].
- Other names
- sunitinib malate + prednisone
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)GR (Glucocorticoid receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on sunitinib + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunitinib + prednisone.